Results 131 to 140 of about 20,899 (290)

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 803-816, February 2026.
Abstract Treatment with GLP‐1 receptor agonists (GLP‐1 RAs) is effective in reducing body weight in individuals with overweight and type 2 diabetes (T2D). However, measurements indicate that a considerable portion of the weight loss derives from fat‐free mass (FFM), including skeletal muscle, which may compromise metabolic health and physical function.
Viktor Aimelet, Jens Juul Holst
wiley   +1 more source

Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities. [PDF]

open access: yesJ Clin Med, 2023
Rodriguez-Torres RS   +10 more
europepmc   +1 more source

Molecular bases of spinal muscular atrophy: the survival motor neuron gene [PDF]

open access: yes, 2001
L'atròfia muscular espinal (AME) és una malaltia neuromuscular autosòmica recessiva caracteritzada per Ia degeneració i Ia pèrdua de Ies motoneurones de Ia banya anterior de Ia medul·la espinal.
Baiget Bastús, Montserrat   +1 more
core  

EAN 2024 Guideline on the Diagnostic Approach to Oligo/Asymptomatic HyperCKemia

open access: yesEuropean Journal of Neurology, Volume 33, Issue 2, February 2026.
ABSTRACT Background Recent epidemiological studies on the general population reveal that up to 1.3% have oligo/asymptomatic hyperCKemia. Objective This guideline aims to provide updated, evidence‐based recommendations on investigating persons older than 18 years.
T. Kyriakides   +15 more
wiley   +1 more source

Considerations for Treatment in Clinical Care of Spinal Muscular Atrophy Patients

open access: yesChildren
Spinal Muscular Atrophy is a neurodegenerative disease which can lead to muscle weakness, paralysis, and in some cases death. There are many factors that contribute to the severity of symptoms and those factors can be used to determine the best course of
Stephanie Voight, Kapil Arya
doaj   +1 more source

The impact of Hnrnpl deficiency on transcriptional patterns of developing muscle cells

open access: yesFEBS Open Bio, Volume 16, Issue 1, Page 178-198, January 2026.
We performed nanopore whole‐transcriptome sequencing comparing RNA from Hnrnpl‐knockdown versus control C2C12 myoblasts to investigate the contributions of Hnrnpl to muscle development. Our results indicate that Hnrnpl regulates the expression of genes involved with Notch signaling and skeletal muscle, particularly splicing patterns of specific muscle ...
Hannah R. Littel   +8 more
wiley   +1 more source

Schwann cell pathology in spinal muscular atrophy (SMA)

open access: yes, 2015
The childhood neuromuscular disease spinal muscular atrophy (SMA) is caused by low levels of survival motor neuron (SMN) protein. Historically, SMA has been characterised as a disease primarily affecting lower motor neurons. However, recent breakthroughs have revealed defects in other non-neuronal cells and tissues. In vivo analysis of peripheral nerve
openaire   +2 more sources

Granular Hydrogels as Modular Biomaterials: From Structural Design to Biological Responses

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 3, 19 January 2026.
Granular hydrogels are now emerging as promising biomaterials due to their inherent microporousity, injectability, and modularity. They have shown improvements in cell viability and migration, cellular/tissue infiltration, host tissue integration, mitigated foreign body response, and tissue regeneration.
Asmasadat Vaziri   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy